Intellia Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Intellia Therapeutics, Inc. Overview

Intellia Therapeutics is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, with a mission to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. 2026 is framed as a pivotal year, with HAELO Phase 3 top-line lonvo-z data expected by mid-year and a planned BLA submission in the second half, positioning the company for potential commercial launch in 2027.

Strategic Profile

Intellia is driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. The company closed 2025 with $605.1 million in cash, sufficient to fund operations into the second half of 2027, with commercial manufacturing, field teams and payer outreach for a possible launch largely in place. The FDA removed the clinical hold on the MAGNITUDE Phase 3 clinical trial of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), marking a major de-risking event.

Competitive Landscape

Management is positioning lonvo-z as a potential first-in-class in vivo CRISPR therapy while managing competitive dynamics in the CRISPR gene editing space. Key competitors include other CRISPR-based therapeutics developers and traditional pharma entities developing ATTR and hereditary angioedema treatments. The competitive advantage centers on Intellia's in vivo delivery capability and advanced clinical stage programs.

Industry Context

Intellia Therapeutics, Inc. operates in Biopharmaceutical - Gene Editing/Gene Therapy.

Key facts

Founded: 2014 · Headquarters: Cambridge, US · Revenue: $23.0M (Q4 2025) · Market cap: $1.77B